Translational Vector Core
The vector core of the Gene Therapy Laboratory of Nantes was created in 1997. The funding is essentially provided by the University, the Hospital (CHU) of Nantes, the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Region Pays de la Loire. The vector core has developed processes for production and characterization of viral vectors derived from adenovirus, adeno-associated virus (AAV). These vectors are intended to use for in vitro and in vivo gene transfer applications, for basic research or for evaluation of therapeutic strategies for cancer or inherited diseases treatment.
Today, the vectors production center (CPV), within the INSERM UMR1089 research unit (translational gene therapy for retinal and neuromuscular diseases), is composed of two groups working together :
A Development group
A vector core
The CPV group and Atlantic Bio GMP are part, together with Genethon and GenoSafe, of the Preindustrial Gene Therapy consortium (PGT) funded since 2011 by the Agence Nationale de la Recherche (ANR) investment program for the future.
Contact
- Responsable opérationnel :
- Contact :
- Françoise Balter, Assistante plate-forme
ltg.production@univ-nantes.fr
- Françoise Balter, Assistante plate-forme